BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
Zacks.com on MSN23h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseAlnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
PNN Ahmedabad Gujarat [India]7 Troikaa Pharma announced that it has launched its Zolpidem Sublingual Spray 385 wv for the ...
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
Delve into the field of miRNA with 7 promising companies with miRNA-focused candidates in the pipeline, from oncology to neurodegeneration.
Specialized centers for cardiomyopathies and amyloid heart disease illustrate the benefits of integrating clinical practice ...
News Medical on MSN2h
Insulin resistance linked to increased risk of aortic stenosisA large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development ...
(IN BRIEF) Researchers at the University of Liverpool have identified a new mechanism in Alzheimer’s disease involving the ...
News Medical on MSN23h
Lower pulmonary gas exchange may be linked to impaired cognitive function in long COVID patientsIn patients with long COVID, lower pulmonary gas exchange may be associated with impaired cognitive function, according to a study being presented next week at the annual meeting of the Radiological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback